Enhancing GLP-1 Therapy Outcomes: The Role of Amylin Analogues and SLM+

Combining GLP-1 therapies with amylin analogues and metabolic enhancers like SLM+ may offer a synergistic approach to weight loss. STAAR LABS’ research provides insights into optimizing GLP-1 therapy outcomes.

Adding Pramlintide to GLP-1 Therapies

Liraglutide + Pramlintide: Liraglutide (11-18 lbs) combined with pramlintide (5-12 lbs) may achieve 20-24 lbs over 52 weeks. Pramlintide enhances satiety and stabilizes blood sugar, complementing GLP-1’s appetite suppression.*
Dulaglutide + Pramlintide: Dulaglutide (11-15 lbs) with pramlintide may achieve 16-20 lbs, offering similar synergistic effects.*

Using SLM+ in Conjunction

Liraglutide + Pramlintide + SLM+: Initial research suggests this combination may support 33-46 lbs over 52 weeks, potentially matching tirzepatide’s efficacy (33-46 lbs) while remaining 503A-compliant. SLM+ may enhance endogenous GLP-1 production, mimic GIP’s metabolic role, and support fat oxidation.*
Dulaglutide + Pramlintide + SLM+: May support 29-42 lbs, surpassing Dulaglutide + Pramlintide alone (16-20 lbs) and offering a legal alternative to semaglutide (22-33 lbs).*

The Power of Synergy

Combining GLP-1 therapies with amylin analogues and metabolic enhancers like SLM+ may address the limitations of standalone GLP-1s, providing a safe, legal option in the post-shortage landscape.* This approach may help patients achieve greater weight loss while managing side effects like fatigue.

Collaborate with STAAR LABS

STAAR LABS welcomes partnerships with pharmacies and providers to explore similar synergistic protocols. Contact us at info@staarlabs.com to learn more.

Stay updated on STAAR LABS’ research. Join our community for insights into optimizing GLP-1 therapy outcomes at STAAR LABS

Legal Disclaimer: These statements have not been evaluated by the Food and Drug Administration (FDA). The information provided is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. SLM+ Gen 2 is in development and not yet available; projected benefits are subject to change pending final results (expected June 2025). Always consult a healthcare provider before starting any new therapy or supplement, especially if using GLP-1 therapies or managing medical conditions. STAAR LABS is not responsible for adverse effects resulting from use.

Other Blogs

Explore the STAAR LABS Blog for insights that elevate your well-being.

View all posts

How to Keep Your Results After Stopping GLP-1s (and Avoid the 70–90% Regain Curve)

GLP-1 therapy delivers meaningful weight loss, but stopping treatment is a critical transition point. Up to 70–90% of patients regain...

Nutrition, Resistance Training, and Supplementation - Protecting Lean Mass on GLP-1s

Weight loss is only half the battle on GLP-1 therapy — keeping lean muscle and protecting your metabolism are just...

Why Basal Metabolic Drive Drops on GLP-1s (and How to Counter It)

GLP-1 medications like semaglutide, liraglutide, and tirzepatide have redefined weight management. By decreasing appetite and improving glucose control, they make...

Collapsible content

Add a short description for this section

References

Disclaimers

Medical Disclaimer:

STAAR LABS is not a licensed pharmacy, medical provider, or drug manufacturer. The information provided is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. SLM+ is a dietary supplement and is not intended to replace prescription medications or medical advice. Patients should consult their licensed healthcare provider before making any changes to their medical treatment, diet, or supplement use.

Trademark Disclaimer:

Ozempic®, Wegovy®, and Saxenda® are registered trademarks of Novo Nordisk A/S.

Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.

STAAR LABS is not affiliated with, sponsored by, or endorsed by Novo Nordisk A/S or Eli Lilly and Company. References to these products are for informational purposes only to describe commonly prescribed GLP-1 therapies.

Research & Innovation Disclosure:

STAAR LABS collaborates with clinics, pharmacies, and healthcare professionals to advance innovation in real-world metabolic health protocols. We welcome research partners committed to improving outcomes through evidence-based nutraceutical and pharmaceutical strategies.